Phase 4 HIV and AIDS Trial, Recruiting (NCT05669534)

Phase 4 HIV and AIDS Trial, Recruiting NCT05669534 Sponsor: University of Connecticut Condition: HIV and AIDS

Printed from Voxsanity (voxsanity.com.au) — NCT05669534 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hiv Aids

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with opioid dependence (according to standard medical guidelines) and have recently been prescribed and are consistently taking medication to treat opioid use disorder (such as methadone or buprenorphine) through the APT Foundation, Inc.
People who show signs of mild cognitive impairment (some difficulty with memory or thinking) based on a specific screening test called the Montreal Cognitive Assessment (MoCA)
People who have started taking PrEP (a daily pill that helps prevent HIV) within the past week
People who have confirmed they do not have HIV, shown through proof of a PrEP prescription
People who report having used injected drugs in an unsafe way, or having had unprotected sex, within the past 3 months
People who own or have access to a cell phone
People who are able to read and understand English

Who may not be able to join:

People who are not able to give their own informed consent to participate
People who are currently having thoughts of ending their own life
People who are currently having thoughts of harming others
People who are currently experiencing psychosis (a serious mental state where a person may lose touch with reality)
People whose MoCA screening score suggests they may have dementia (a more severe level of cognitive decline)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Michael Copenhaver, PhD, University of Connecticut

Phone: 2037814690

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05669534

Sponsor: University of Connecticut

Phase: Phase 4

Status: Recruiting

Condition: HIV and AIDS

Trial contact: 2037814690

More information: https://clinicaltrials.gov/study/NCT05669534

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with opioid dependence (according to standard medical guidelines) and have recently been prescribed and are consistently taking medication to treat opioid use disorder (such as methadone or buprenorphine) through the APT Foundation, Inc.
People who show signs of mild cognitive impairment (some difficulty with memory or thinking) based on a specific screening test called the Montreal Cognitive Assessment (MoCA)
People who have started taking PrEP (a daily pill that helps prevent HIV) within the past week
People who have confirmed they do not have HIV, shown through proof of a PrEP prescription
People who report having used injected drugs in an unsafe way, or having had unprotected sex, within the past 3 months
People who own or have access to a cell phone
People who are able to read and understand English

Who may not be able to join:

People who are not able to give their own informed consent to participate
People who are currently having thoughts of ending their own life
People who are currently having thoughts of harming others
People who are currently experiencing psychosis (a serious mental state where a person may lose touch with reality)
People whose MoCA screening score suggests they may have dementia (a more severe level of cognitive decline)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

University of Connecticut

Registry

ClinicalTrials.gov

Start date

1 March 2023

Est. completion

1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pre-Exposure Prophylaxis Adherence via Dried Blood Spots (DBS); Pre-Exposure Prophylaxis Adherence via Dried Blood Spots (DBS); Pre-Exposure Prophylaxis Adherence via Dried Blood Spots (DBS); Pre-Exposure Prophylaxis Adherence via Dried Blood Spots (DBS); Pre-Exposure Prophylaxis Adherence via pharmacy refill data; Pre-Exposure Prophylaxis Adherence via pharmacy refill data; Pre-Exposure Prophylaxis Adherence via pharmacy refill data; Pre-Exposure Prophylaxis Adherence via pharmacy refill data; Pre-Exposure Prophylaxis Adherence via self-report scale; Pre-Exposure Prophylaxis Adherence via sel...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov